Malley Thomas 4

Accession 0001415889-25-021941

CIK 0001730430other

View on SEC.gov Company Profile

Filed

Aug 13, 8:00 PM ET

Accepted

Aug 14, 4:59 PM ET

Size

35.1 KB

Accession

0001415889-25-021941

Insider Transaction Report

Form 4

Period: 2025-08-12

Kiniksa Pharmaceuticals International, plcKNSA

Malley Thomas

Director

Transactions

Exercise/Conversion
Class A Ordinary Shares
2025-08-12$3.80/sh+27,448$104,302→ 61,953 total
Sale
Class A Ordinary Shares
2025-08-13$33.32/sh−50,129$1,670,298→ 12,546 total
Exercise/Conversion
Class A Ordinary Shares
2025-08-12$1.86/sh+21,959$40,844→ 34,505 total
Sale
Class A Ordinary Shares
2025-08-12$32.40/sh−49,407$1,600,787→ 12,546 total
Exercise/Conversion
Class A Ordinary Shares
2025-08-13$10.36/sh+20,129$208,536→ 32,675 total
Exercise/Conversion
Class A Ordinary Shares
2025-08-13$9.88/sh+30,000$296,400→ 62,675 total
Exercise/Conversion
Class A Ordinary Shares
2025-08-14$15.47/sh+18,760$290,217→ 31,306 total
Exercise/Conversion
Class A Ordinary Shares
2025-08-14$14.33/sh+33,237$476,286→ 64,543 total
Exercise/Conversion
Class A Ordinary Shares
2025-08-14$15.19/sh+26,236$398,525→ 90,779 total
Sale
Class A Ordinary Shares
2025-08-14$33.09/sh−78,233$2,588,730→ 12,546 total
Exercise/Conversion
Share Option
2025-08-12−21,959→ 0 total
Exercise: $1.86Exp: 2026-12-06→ Class A Ordinary Shares (21,959 underlying)
Exercise/Conversion
Share Option
2025-08-12−27,448→ 0 total
Exercise: $3.80Exp: 2027-06-28→ Class A Ordinary Shares (27,448 underlying)
Exercise/Conversion
Share Option
2025-08-13−20,129→ 0 total
Exercise: $10.36Exp: 2028-02-29→ Class A Ordinary Shares (20,129 underlying)
Exercise/Conversion
Share Option
2025-08-13−30,000→ 0 total
Exercise: $9.88Exp: 2032-06-28→ Class A Ordinary Shares (30,000 underlying)
Exercise/Conversion
Share Option
2025-08-14−18,760→ 0 total
Exercise: $15.47Exp: 2029-05-28→ Class A Ordinary Shares (18,760 underlying)
Exercise/Conversion
Share Option
2025-08-14−33,237→ 0 total
Exercise: $14.33Exp: 2031-06-28→ Class A Ordinary Shares (33,237 underlying)
Exercise/Conversion
Share Option
2025-08-14−26,236→ 0 total
Exercise: $15.19Exp: 2033-06-04→ Class A Ordinary Shares (26,236 underlying)

Holdings

Class A Ordinary Shares
(indirect: See footnote)
71,967

Footnotes (5)

[F1]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.06 and $32.685. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.1301 and $33.50. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.82 and $33.41. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F4]Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock.
[F5]The option is fully vested and exercisable.

Documents

1 file

4
form4-08142025_080859.xmlPrimary

Issuer

Kiniksa Pharmaceuticals International, plc

CIK 0001730430

→

Entity typeother

Related Parties

filerCIK 0001403322

Filing Metadata

Form type: 4
Filed: Aug 13, 8:00 PM ET
Accepted: Aug 14, 4:59 PM ET
Size: 35.1 KB

View on SEC.gov